Methotrexate: A Gold Standard for Treatment of Rheumatoid Arthritis

REFERENCES

• Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Cl Rh. 2003;17:811–829.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology. Rheumatoid arthritis. Available at: http://www.rheumatology.org/practice/clinical/patients/diseases and conditions/ra.asp. Updated August 2012. Accessed December 9, 2013.
   Google Scholar
• Lipsky PE, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology (Oxford). 1999;38(Suppl 2):41–44.
   Google Scholar
• Misra R, Sharma BL, Gupta R, Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. Indian J Rheumatol. 2008;3:S1–S16.
   Google Scholar
• Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis. 1998;47:2–7.
   Google Scholar
• Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270:119–125.
   PubMed Web of Science ®Google Scholar
• Toxicology Data Network Methotrexate (xxx = Methotrexate). Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3123. Updated May 2011. Accessed December 14, 2013.
   Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Safety Data Sheet. Methotrexate. Availabe at www.usp.org/pdf/EN/referenceStandards/msds/1414003.pdf.
   Google Scholar
• Robbins PD, Evans CH. Rheumatoid arthritis. Gene therapy. Sci Am Sci Med. 1998;5:6–7.
   Google Scholar
• Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum. 1997;27:123–140.
   PubMed Web of Science ®Google Scholar
• Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26:35–61.
   PubMed Web of Science ®Google Scholar
• Leigh JP, Fries JF. Arthritis and mortality in the epidemiological follow-up to the National Health and Nutrition Examination Survey I. Bull N Y Acad Med. 1994;71:69–86.
   PubMedGoogle Scholar
• Pincus T, Callahan LF, Sale WG, Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864–872.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Siblety JT, The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–494.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–1697.
   PubMed Web of Science ®Google Scholar
• Meune C, Touze E, Trinquart L, Trends in cardiovascular mortalityin patients with rheumatoid arthritis over 50 years: a systematicreview and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48:1309–1313.
   PubMed Web of Science ®Google Scholar
• Sacks JJ, Helmick CG, Langmaid G. Deaths from arthritis and other rheumatic conditions, United States, 1979–1998. J Rheumatol. 2004;31:1823–1828.
   PubMed Web of Science ®Google Scholar
• Dadouna S, Zeboulon-Ktorzab N, Combescurec C, Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80:29–33.
   Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis, Ann Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Magne D, Palmer G, Barton J, The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther. 2006;8(3):1–11. R80. (doi: 10.1186/ar1946)
   Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl J Med. 2001;344:907–916.
   PubMed Web of Science ®Google Scholar
• Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000;12:1092–1110.
   PubMed Web of Science ®Google Scholar
• Schuna AA. Update on treatment of rheumatoid arthritis. J Am Pharm Assoc. 2014;38(6):728–735.
   Google Scholar
• Larsen C, Ostergaard J, Larsen SW, Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008;97:4622–4654.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729–735.
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–911.
   PubMed Web of Science ®Google Scholar
• Tarner IH, Muller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv. 2008;5:1027–1037.
   PubMed Web of Science ®Google Scholar
• Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42:139–151.
   PubMed Web of Science ®Google Scholar
• Genestier L. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247–257.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Antiproliferative and anti-inflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol. 2000;27:2551–2557.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23:739–55
   PubMed Web of Science ®Google Scholar
• Langer R. Where a pill won't reach. Sci Am. 2003;288:50–57.
   PubMed Web of Science ®Google Scholar
• Cronstein B. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57: 163–172.
   PubMed Web of Science ®Google Scholar
• Campbell MA, Perrier DG, Dorr RT, Alberts DS, Finley PR. Methotrexate: bioavailability and pharmacokinetics. Cancer Treat Rep. 1985;69:833–838.
   PubMedGoogle Scholar
• Sahoo S, Aurich MK, Jonsson JJ, Thiele I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Front Physiol. 2014;5:1–24. (doi: 10.3389/fphys.2014.00091)
   Google Scholar
• Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. Epub ahead of print April 12, 2014;73(8):1549–1551. doi: 10.1136/annrheumdis-2014-205228.
   Google Scholar
• Chaudhary R, Qureshi S, Patel J, Panigrahi UP, Giri IC. Formulation, development and in-vitro evaluation of mucoadhesive buccal patches of methotrexate. Int J Pharma Sci Res. 2010;1:357–365.
   Google Scholar
• Narayani R, Panduranga Rao K. pH-responsive gelatin microspheres for oral delivery of anticancer drug methotrexate. J Appl Polym Sci. 1995;58:1761–1769.
   Web of Science ®Google Scholar
• Rathor S, Ram A. Floating drug delivery system as an approach to increase the gastric retention of methotrexate: formulation and evaluation. Asian J Pharm Clin Res. 2013;6(1):42–47.
   Google Scholar
• Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol. 2010;22:330–335.
   PubMed Web of Science ®Google Scholar
• Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcom AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010;1:109–131.
   PubMedGoogle Scholar
• Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in Rheumatic diseases. Drugs. 2000;60:555–574.
   PubMed Web of Science ®Google Scholar
• Yanga F, Kamiyaa N, Goto M. Transdermal delivery of the anti-rheumatic agent methotrexate using a solid-in-oil nanocarrier. Eur J Pharm Biopharm. 2012;82:158–163.
   Google Scholar
• Sharma A, Arora S. Formulation and in vitro evaluation of ufasomes for dermal administration of methotrexate. ISRN Pharm. 2012;2012:1–11. doi: 10.5402/2012/873653.
   Google Scholar
• Michael J. Akers. Parenteral Preparations. In: Linda A. Felton, editor. Remington: Essentials of Pharmaceutics. 1st ed. London. Pharmaceutical Press; 2013.
   Google Scholar
• Braun J, Kastner P, Flaxenberg P, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.
   PubMed Web of Science ®Google Scholar
• Visser K, Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68:1094–1099.
   PubMed Web of Science ®Google Scholar
• Williams AS. Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant induced arthritis. Clin Exp Immunol. 1995;102:560–565.
   PubMed Web of Science ®Google Scholar
• Prabhu P. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomed. 2012;7: 177–186.
   PubMed Web of Science ®Google Scholar
• Udupa N, Chandraprakash KS, Umadevi P, Pillai GK. Formulation and evaluation of methotrexate niosomes. Drug Dev Ind Pharmacy. 1993;19:1331–1342.
   Web of Science ®Google Scholar
• Venkatesh MP, Anis S, Pramod Kumar TM. Design and development of an injectable in situ forming drug delivery system of methotrexate for the treatment of rheumatoid arthritis. J Drug Deliv Sci Technol. 2013;23:445–453.
   Web of Science ®Google Scholar
• Butoescu N, Jordan O, Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm. 2009;73:205–218.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–160.
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL, Thomas DP, Wraight P. Liposomes in arthritis: a new approach. Lancet. 1979;1:1320–1322.
   PubMed Web of Science ®Google Scholar
• Williams AS, Cammilleri JP, Goodfellow RM, Williams BD. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br J Rheumatol. 1996;35:719–724.
   PubMedGoogle Scholar
• Stehle G, Wunder A, Sinn H, Pharmacokinetic of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs. 1997;8:835–844.
   PubMed Web of Science ®Google Scholar
• Wunder A, Muller-Ladner U, Stelzer EH, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003;170:4793–4801.
   PubMed Web of Science ®Google Scholar
• Wunder A. Antitumor activity of methotrexate albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer. 1998;76:884–890.
   PubMedGoogle Scholar
• Liang LS. Methotrexate loaded poly(l-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci. 2004;93:943–956.
   PubMed Web of Science ®Google Scholar
• Miao B, Song C, Ma G. Injectable thermosensitive hydrogels for intra-articular delivery of methotrexate. J Appl Polym Sci. 2011;122:2139–2145.
   Web of Science ®Google Scholar
• Venkatesh MP, Liladhar PK, Teggin MP, Shivakumar HG. In situ gels based drug delivery systems. Curr Drug Therapy. 2011;6:213–222.
   Google Scholar
• Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol. 2002;29:2077–2083.
   PubMed Web of Science ®Google Scholar
• O'Dell JR, Leff R, Paulsen G, Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two-year, randomized, double-blind, placebo controlled trial. Arthritis Rheum. 2002;46:1164–1170.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Don't forget traditional DMARDs. Rheumatology. 2011;50:429–430.
   Google Scholar
• Fleischmann RM. Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? Rheum Dis Clin North Am. 2006;32:21–28.
   Google Scholar